The author reviews the impact of neuroleptic chemotherapy on various
forms of schizophrenia in the 25 years since the introduction of
chlorpromazine in psychiatry. The activities of the different types of
compounds are related to the symptomatic and progressive forms of the
psychosis, with an emphasis on the "dual structure" of the illness.
Problems of drug efficacy, the need for new drug treatments, and
methodological issues in research in these areas are discussed.